Current clinical approaches for overcoming resistance to EGFR-TKIs in NSCLC include the use of mutant-selective inhibitors of EGFR, a combination of cetuximab and afatinib, and a combination of EGFR-TKI with a drug inhibiting a resistance pathway, for example erlotinib used together with a MET inhibitor [10–14]. Here, MET is linked to non-small cell lung carcinoma.